Reassure patients about the self-limiting nature of the condition, and that symptoms usually clear within 7 to 10 days. The severity and duration of symptoms appear to be related to what the patient believes and feels about the treatment received, and empathetic treatment, as perceived by the patient, is associated with improvement in symptoms and biochemical markers. Advise patients about hygiene measures and limiting the spread to others, as well as the importance of rest and maintaining fluid intake to stay hydrated. The implications of increased fluid intake in acute respiratory infections have not been studied in any trials to date.
Symptomatic relief is the mainstay of treatment. Many over-the-counter medications claim to alleviate symptoms of the common cold; however, quality evidence to support the use of these medications is limited.
Fever and pain
Acetaminophen is recommended for pain and/or fever. Evidence suggests that it may also help with nasal congestion and rhinorrhea, but not sore throat, malaise, sneezing, or cough. Despite this, it is still one of the most widely used analgesic/antipyretic agents, and is a first choice for many clinicians for the management of pain and fever in both adults and children.
A review of nonsteroidal anti-inflammatory drugs (NSAIDs) found benefit for reducing discomfort, but found no benefit in terms of easing respiratory symptoms. Possible adverse effects need to be considered (e.g., gastrointestinal adverse effects, rash). [ ] Studies of aspirin have found it to be effective for pain and fever, without serious gastrointestinal adverse effects with short-term use, although a small increased risk of dyspepsia has been reported. Aspirin should be avoided in children and adolescents under 18 years of age because of the risk of Reye syndrome.
Analgesics are available as single-agent or combination (with decongestants and/or antihistamines) formulations.
There are many different formulations of decongestants and/or antihistamines available over the counter for the treatment of nasal symptoms (i.e., congestion, rhinorrhea, sneezing), including single-agent and combination formulations.
In adults, decongestants and/or antihistamines are the best option for patients with bothersome nasal symptoms; however, the effect is considered small.
Sympathomimetic decongestants are available in oral (e.g., pseudoephedrine) or intranasal (e.g., oxymetazoline) formulations. There is no evidence to support the use of one route of administration over another. A Cochrane review found a small subjective decrease in nasal congestion from multiple doses of nasal decongestants (3 to 4 doses per day over 5 to 10 days), but it was unclear whether this was beneficial for patients.
Oxymetazoline nasal spray has been shown to have an effect in reducing airway resistance, but there is limited evidence on patient-oriented benefits. Intranasal decongestants should be used for a maximum of 3 to 7 days due to the risk of chronic/rebound nasal congestion (rhinitis medicamentosa).
A Cochrane review found that (older, first-generation) sedating antihistamines are associated with relief of sneezing and rhinorrhea, but not nasal congestion; sedation is commonly reported. Studies evaluating (newer, second-generation) nonsedating antihistamines show an unclear effect on nasal congestion, with no effect on sneezing or rhinorrhea.
Combination formulations of decongestants and antihistamines
Antihistamines and decongestants are often formulated together, with or without an analgesic. Certain combinations of these agents may improve congestion, rhinorrhea, and sneezing; however, the quality of trial data for these formulations is weak. Adverse effects include headache, sedation, and insomnia. [ ]
A systematic review found low-quality evidence to suggest ipratropium nasal spray is effective for rhinorrhea compared with placebo, but not for nasal congestion. Adverse effects (e.g., dry mouth, nose bleeds, nasal dryness) were more frequent compared with placebo or no treatment.
In children, the evidence for these treatments is more limited. There is no evidence that decongestants alleviate nasal symptoms in children, and they are known to cause adverse effects (e.g., drowsiness, gastrointestinal upset, more serious harms such as convulsions and rapid heart rate, and death). Therefore, decongestants are not recommended in children <6 years of age, and caution is recommended in children ages 6 to 12 years. The Food and Drug Administration does not recommend cold products that contain a decongestant and/or antihistamine in children under 4 years of age due to possible serious and life-threatening adverse effects. The advice differs in other countries. For example, in the UK and Canada, over-the-counter cold treatments are not recommended at all in children under 6 years of age.
There is low-quality evidence that saline drops or sprays may be effective and safe in younger children. They improve nasal congestion in older children, and possibly reduce rhinorrhea severity.
Despite these warnings, data from the Pediatric Cough and Cold Safety Surveillance System indicate that the overall rate of adverse effects related to over-the-counter cough and cold medications in children <12 years of age is relatively low (1 adverse effect per 1.75 million dose units sold), with 67% of adverse effects being related to accidental unsupervised ingestion. Fatalities were extremely rare (0.6% of patients) and not associated with therapeutic doses.
Many different cough suppressants or expectorants are available, including single-agent and combination formulations (often combined with decongestants and/or antihistamines). There is no evidence to support or refute the use of over-the-counter antitussive agents, expectorants, or mucolytic agents to reduce the incidence of cough in adults or children, particularly young children. However, the American College of Chest Physicians recommends against the use of over-the-counter cough and cold medicines for the treatment of cough.[Evidence C]
Cough and cold medications that include opioids, such as codeine or hydrocodone, should not be used in children aged 18 years or younger as the risks (slowed or difficult breathing, misuse, abuse, addiction, overdose, and death) outweigh the benefits when used for cough in these patients.
Honey has been shown to offer more relief of cough symptoms compared to no treatment, placebo, and diphenhydramine in children aged 1 to 18 years, but is not better than dextromethorphan.[Evidence C]
A review of inhaled corticosteroids for acute and subacute cough found insufficient evidence to recommend their routine use for acute respiratory tract infections in adults. However, some trials have shown benefits, suggesting the need for further high-quality, adequately powered trials.
Antibiotics are not effective for symptoms of the common cold and are known to cause adverse effects. The Centers for Disease Control and Prevention, and the American College of Physicians do not recommend antibiotic treatment. Regulatory bodies in other countries also support this recommendation.
Antibiotics are often requested by patients at consultation, but there is increasing evidence that this encourages resistant strains of bacteria and causes unnecessary harm. There is limited evidence that purulent nasal discharge (interpreted by many clinicians and patients as suggestive of bacterial infection) will not respond to antibiotics. A delayed prescription for antibiotics, alongside advice on the natural history of the illness and symptomatic treatments, has been found to reduce the rate of antibiotic use (31%) compared with immediate antibiotics (93%) with similar rates of patient satisfaction. Providing written information about the use of antibiotics to parents of children with upper respiratory tract infections can also reduce the number of antibiotics used without affecting parental satisfaction. Other interventions that may have an effect on reducing antibiotic prescribing in acute respiratory tract infections in a primary care setting include C-reactive protein testing, procalcitonin-guided management of infections, and shared decision making between doctors and their patients; however, there is only moderate quality evidence for these interventions. [ ]
Other treatments with limited or no evidence of efficacy
No other treatments are supported by adequate evidence. Interventions such as oral and nasally inhaled zinc, echinacea, and humidified air have all been studied in placebo-controlled trials. Overall, they have shown minimal evidence of effectiveness.
Vitamin C supplementation has been found to have no benefit on the incidence of colds. While one study found that vitamin C may reduce the duration of colds, systematic reviews (that included seven randomized controlled trials) found that vitamin C had minimal or no impact on the duration of the common cold in terms of the number of days at home or out of work. However, administration of extra therapeutic doses of vitamin C at the onset of a cold, in addition to routine supplementation, has been found to reduce the duration of colds, shorten the time of indoor confinement, and provides symptomatic relief of chest pain, fever, and chills.
Commercial inhalant products are popular, although evidence from clinical trial data to support efficacy is limited. Studies evaluating a combination of intranasal and inhaled cromolyn sodium found inconclusive evidence of effectiveness. There is some evidence for the effectiveness of vapor rubs in providing symptomatic relief. Based on current evidence, there is no role for intranasal corticosteroids in the treatment of common cold.
Treatments for which there is evidence of benefit from a single trial or from poor-quality trials include green tea, garlic, various Chinese herbal medicines, Huo Xiang Zhengqi dropping pill, African geranium, and Pelargonium sidoides (also known as umckaloabo). There is limited evidence that sea buckthorn has no effect. A systematic review found evidence to support the use of black elderberry (Sambucus nigra) to reduce upper respiratory symptoms. A Cochrane review found that homeopathic products did not show any benefit in terms of cure rates or prevention of acute respiratory infections in children compared to placebo.
Use of this content is subject to our disclaimer